Search
Azficel-T
go.drugbank.com/drugs/DB11051ApprovedWithdrawnExpanded cells are then suspended in a cell medium. … As a replacement for lost dermal constituents in the aging or skin deformation process, treatment with autologous fibroblasts has shown to improve wrinkle and acne scar appearance than with placebo treatment
Alfacalcidol
go.drugbank.com/drugs/DB01436ApprovedInvestigationalNutraceuticalThe pharmacological actions of alfacalcidol are prolonged than vitamin D because a negative feedback mechanism regulates the final activation step of vitamin D in the kidneys. … Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of [vitamin D].
Products: ALFACALCIDOL 1A PHAR0.5UG, ALFACALCIDOL 1A PHAR0.25UGInotersen
go.drugbank.com/drugs/DB14713ApprovedInvestigationalInotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. … It was FDA approved in October 2018.
Chromic chloride
go.drugbank.com/drugs/DB09129ApprovedChromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).
Mixtures: One-A-day Advance Men's, M T E 4 Concentrate InjCategories: Compounds used in a research, industrial, or household settingEladocagene exuparvovec
go.drugbank.com/drugs/DB16780ApprovedInvestigationalEladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal … [L43642] Eladocagene exuparvovec received EMA approval in July 2022.
Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity … It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with [DB00947].
Categories: MATE 1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexBrincidofovir
go.drugbank.com/drugs/DB12151ApprovedInvestigationalBrincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. … The approval was granted under the agency’s Animal Rule,[L34480] which allows for a drug to be approved based on the results of well-controlled animal studies when human trials would be unethical or infeasible
Gadolinium
go.drugbank.com/drugs/DB12091ApprovedInvestigationalWithdrawnGadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease.
Categories: Compounds used in a research, industrial, or household settingAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalAlectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. … Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexLevamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigationalLevamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. … [A188940] Levamlodipine was granted FDA approval on 19 December 2019.[L10833]